Same Indication

Ipilimumab vs Ranitidine

Ipilimumab vs Ranitidine: Overview

This comparison examines the pharmacological differences between Ipilimumab and Ranitidine.

Mechanism of Action

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Ranitidine: Competitive H2 receptor antagonist.

Pharmacokinetics

Half-life: Ipilimumab — 14.7 days; Ranitidine — 2-3 hours.

Chemical Properties

Molecular Formula: Ranitidine — C13H22N4O3S.

Molecular Weight: Ranitidine — 314.4050 g/mol.

Type: Ipilimumab — Antibody; Ranitidine — Small molecule.